As of June 10, 2025, Abbvie Inc (ABBV) reports a EV/EBITDA of 18.20.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Abbvie Inc's EV/EBITDA to Peers
To better understand Abbvie Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Abbvie Inc (ABBV) | 18.20 |
| Vericel Corp (VCEL) | 502.26 |
| Neurocrine Biosciences Inc (NBIX) | 23.24 |
| Exelixis Inc (EXEL) | 17.87 |
| Biomarin Pharmaceutical Inc (BMRN) | 14.87 |
| ACADIA Pharmaceuticals Inc (ACAD) | 14.04 |
Compared to its competitors, Abbvie Inc's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.